Managing Hypertension in Achondroplasia
Follow standard hypertension guidelines for patients with achondroplasia, as there is no evidence requiring modified blood pressure targets or different medication choices in this population. The absence of achondroplasia-specific hypertension data means treatment should align with current AHA/ACC and ESC guidelines while accounting for the unique anatomical considerations of these patients 1, 2.
Blood Pressure Targets
Target systolic BP of 120-129 mmHg in most adults with achondroplasia, provided treatment is well tolerated 2. This recommendation applies regardless of the presence of achondroplasia, as:
- Recent cardiovascular risk factor studies show adults with achondroplasia actually have lower blood pressure, cholesterol, and visceral fat compared to BMI-matched controls, despite high BMI values 3
- The increased cardiovascular mortality reported in achondroplasia appears related to factors other than traditional risk factors 3
- Standard BP targets have demonstrated CVD risk reduction across diverse populations 2
If the 120-129 mmHg target is poorly tolerated, apply the ALARA principle (as low as reasonably achievable) 2.
Medication Selection
First-Line Therapy
Initiate combination therapy immediately for confirmed hypertension (BP ≥140/90 mmHg) using 2:
- RAS blocker (ACE inhibitor or ARB) PLUS
- Dihydropyridine calcium channel blocker OR thiazide/thiazide-like diuretic
- Preferably as a single-pill combination to improve adherence 2
Key consideration: No evidence suggests achondroplasia requires different drug classes. The standard first-line agents (ACE inhibitors, ARBs, CCBs, thiazides) have proven CVD event reduction and are appropriate 2.
Escalation Strategy
If BP remains uncontrolled:
- Three-drug combination: RAS blocker + CCB + thiazide/thiazide-like diuretic (preferably single-pill) 2
- Add spironolactone if three-drug combination fails 2
- Consider eplerenone, beta-blocker (if not already indicated), centrally-acting agent, alpha-blocker, or hydralazine if spironolactone ineffective/not tolerated 2
Never combine two RAS blockers (ACE inhibitor + ARB) 2.
Critical Anatomical Considerations
While medication choices don't change, anatomical factors unique to achondroplasia require attention:
Monitoring Challenges
- Foramen magnum stenosis and spinal stenosis are common complications 4, 5
- Standard BP cuff sizing may be problematic due to short, disproportionate limbs—ensure proper cuff fit for accurate readings
- Home blood pressure monitoring (HBPM) is particularly valuable given measurement challenges 1
Orthostatic Hypotension Risk
- Spinal stenosis and neurological complications may increase orthostatic hypotension risk 4
- Check orthostatic vital signs before and during treatment intensification
- If symptomatic orthostatic hypotension develops, this is an exception where monotherapy may be preferred initially 2
Implementation Strategy
Team-Based Care Approach
Utilize team-based care for optimal BP control 1:
- Primary care clinician for overall management
- Pharmacist for medication optimization and adherence
- Nurse for HBPM education and follow-up
- Consider telehealth interventions to improve access and BP control 1
Follow-Up Schedule
- Monthly evaluations after initiating or intensifying therapy until BP controlled 1
- Assess medication adherence and treatment response at each visit
- Preferably achieve control within 3 months 2
- Once controlled, continue lifelong treatment even beyond age 85 if tolerated 2
Lifestyle Modifications
Implement concurrent lifestyle interventions (not sequential) 2:
- Mediterranean or DASH diet
- Limit alcohol to <100g/week (preferably avoid completely)
- Restrict free sugar to <10% of energy intake
- Smoking cessation if applicable
- Physical activity adapted to skeletal limitations
Important caveat: The high BMI commonly seen in achondroplasia (mean 33.3 kg/m²) 3 does not correlate with traditional cardiovascular risk in this population—they have paradoxically lower visceral fat and better lipid profiles than BMI-matched controls. Don't over-emphasize weight loss as a primary intervention.
Common Pitfalls to Avoid
- Don't delay pharmacological therapy waiting for lifestyle changes alone—guidelines recommend concurrent initiation 2
- Don't use standard BMI cutoffs to assess cardiovascular risk—achondroplasia patients have different body composition 3
- Don't assume increased cardiovascular mortality means more aggressive BP targets are needed—standard targets apply
- Don't overlook proper BP measurement technique given limb length discrepancies
- Don't forget to screen for sleep apnea (common in achondroplasia), which can worsen hypertension control 4, 5
Evidence Gaps
The literature on achondroplasia complications in adults remains limited 6, 7. No studies specifically address hypertension management modifications in this population. The cardiovascular literature focuses primarily on surgical interventions 8 and anesthetic management 9, not medical management of hypertension. This absence of contradictory evidence supports using standard guidelines rather than creating achondroplasia-specific protocols without supporting data.